BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence

• Status: Completed
• Trial end date: 2020-07-21
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in participants with overactive bladder and urinary incontinence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months

• Inadequate response or limiting side effects with pharmacotherapy for the treatment of OAB

Exclusion Criteria:

• Overactive Bladder caused by neurological condition

• Patient has predominance of stress incontinence

• History or evidence of pelvic or urological abnormality

• Prior use of BOTOX for any urological condition